Skip to main content
Department of Health Department of Health An Roinn Sláinte Männystrie O Pouste

Main navigation

  • Home
  • Topics
  • Publications
  • Consultations
  • Contact

Translation help

Translate this page

Select a language

  • Arabic — عربي
  • Chinese (Simplified) — 中文简体
  • Chinese (Traditional) — 中文繁體
  • Dutch — Nederlands
  • Filipino — Filipino
  • French — Français
  • German — Deutsch
  • Hungarian — Magyar
  • Irish — Gaeilge
  • Italian — Italiano
  • Latvian — Latviešu
  • Lithuanian — Lietuvių kalba
  • Polish — Polski
  • Portuguese — Português
  • Romanian — Română
  • Russian — Русский
  • Slovak — Slovenčina
  • Spanish — Español
  • Ukrainian — Українська
  • DoH Policies screened during the period 1 July – 30 September

    Date published: 1 December 2023

    In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.

    Documents

    • NICE Technology Appraisal TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (PDF 511KB)Adobe PDF (510.48 KB)
    • NICE Technology Appraisal TA900 - Tixagevimab plus cilgavimab for preventing COVID-19 (PDF 630KB)Adobe PDF (629.13 KB)
    • NICE Technology Appraisal TA902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (PDF 515KB)Adobe PDF (514.36 KB)
    • NICE Technology Appraisal TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (PDF 511KB)Adobe PDF (510.61 KB)
    • NICE Technology Appraisal TA905 - Upadacitinib for previously treated moderately to severely active Crohn’s disease (PDF 511KB)Adobe PDF (510.26 KB)
    • NICE Technology Appraisal TA904 - Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (PDF 516KB)Adobe PDF (515.05 KB)
    • NICE Clinical Guideline NG232 - Head injury: assessment and early management (updates and replaces CG176) (PDF 516KB)Adobe PDF (515.94 KB)
    • NICE Technology Appraisal TA909 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (PDF 510KB)Adobe PDF (509.66 KB)
    • NICE Technology Appraisal TA906 - Rimegepant for preventing migraine (PDF 513KB)Adobe PDF (512.97 KB)
    • NICE Technology Appraisal TA907 - Deucravacitinib for treating moderate to severe plaque psoriasis (PDF 512KB)Adobe PDF (511.93 KB)
    • NICE Technology Appraisal TA908 - Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (review of TA620) (PDF 512KB)Adobe PDF (511.74 KB)
    • NICE Technology Appraisal TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (PDF 511KB)Adobe PDF (510.59 KB)
    • New Decade New Approach IVF commitment (PDF 531KB)Adobe PDF (530.39 KB)
    • SPPG Consideration of the annual inflationary increase for Foster Care Allowances (boarded out rates) in Northern Ireland (NI) for 2023/24 (PDF 956KB)Adobe PDF (956 KB)
    Share this page Share on Facebook (external link opens in a new window / tab) Share on X (external link opens in a new window / tab) Share by email (external link opens in a new window / tab)

    Department footer links

    • Crown copyright
    • Terms and Conditions
    • Privacy
    • Cookies
    • Accessibility
    • The Northern Ireland Executive
    • The Executive Office
    • Department of Agriculture, Environment and Rural Affairs
    • Department for Communities
    • Department for Education
    • Department for the Economy
    • Department of Finance
    • Department for Infrastructure
    • Department for Health
    • Department of Justice
    • nidirect.gov.uk — the official government website for Northern Ireland citizens